Sonoma Pharmaceuticals and Inotiv Compared

Which small-cap medical company is the superior stock?

Mar. 10, 2026 at 12:10am

Got story updates? Submit your updates here. ›

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but a comparison of the two reveals key differences in factors like institutional ownership, analyst recommendations, and financial performance.

Why it matters

Understanding the relative strengths and weaknesses of these two companies can help investors make more informed decisions about which stock may be the better investment option.

The details

The analysis compares Sonoma Pharmaceuticals and Inotiv across metrics like revenue, earnings per share, net margins, return on equity, and institutional ownership. It also looks at analyst recommendations and price targets, as well as the volatility of each stock.

  • The analysis is based on data as of March 10, 2026.

The players

Sonoma Pharmaceuticals

A pharmaceutical company that develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health, eye care, oral care, and dermatological conditions.

Inotiv

A provider of nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key differences between these two small-cap medical companies, with Inotiv appearing to have stronger financial performance, institutional support, and analyst sentiment compared to Sonoma Pharmaceuticals. Investors should carefully consider these factors when evaluating which stock may be the better investment option.